- Home
- ADRX vs AUPH Comparison
ADRX vs AUPH Comparison
Compare ADRX & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ADRX | AUPH |
|---|---|---|
| Founded | 2019 | 1993 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 2.2B |
| IPO Year | 2026 | 2014 |
Fundamental Metrics
Financial Performance| Metric | ADRX | AUPH |
|---|---|---|
| Price | $14.58 | $15.85 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 7 |
| Target Price | ★ $34.25 | $18.29 |
| AVG Volume (30 Days) | 396.7K | ★ 862.3K |
| Earning Date | 11-12-2026 | 10-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.76 |
| Revenue | N/A | ★ $283,055,000.00 |
| Revenue This Year | $89.41 | $16.65 |
| Revenue Next Year | $510.33 | $17.73 |
| P/E Ratio | ★ N/A | $21.29 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.50 | $13.52 |
| 52 Week High | $19.57 | $19.25 |
Technical Indicators
Market Signals| Indicator | ADRX | AUPH |
|---|---|---|
| Relative Strength Index (RSI) | 39.02 | 41.44 |
| Support Level | $12.50 | $15.67 |
| Resistance Level | $18.94 | $16.48 |
| Average True Range (ATR) | 1.59 | 0.55 |
| MACD | -0.16 | -0.11 |
| Stochastic Oscillator | 30.24 | 6.56 |
Price Performance
Historical ComparisonAbout ADRX ADARx Pharmaceuticals Inc. Common Stock
Adarx Pharmaceuticals Inc is a late-clinical stage biotechnology company focused on developing next-generation siRNA therapeutics designed to treat a broad spectrum of diseases. Its pipeline includes three clinical-stage programs and two advanced preclinical programs. The three hepatic-targeted programs are agazisiran, onvuzosiran, and ADX-626, while the two extrahepatic-targeted programs are ADX-077 and ADX-199.
About AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing aritinercept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.